Big Pharma Finally Looks to RNAi as Drug Source with Merck, Alnylam Deal

For some time, many big biopharmaceutical players have been using RNAi for target discovery and validation...Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.